Low plasma orexin-A levels were improved by continuous positive airway pressure treatment in patients with severe obstructive sleep apnea-hypopnea syndrome

Shigeru Sakurai, Tsuguo Nishijima, Susumu Takahashi, Kohei Yamauchi, Zenei Arihara, Kazuhiro Takahashi

Research output: Contribution to journalArticlepeer-review

49 Citations (Scopus)

Abstract

Introduction: We have previously shown that plasma levels of orexin-A, a neuropeptide with an arousal-stimulating action, were decreased in parallel with the severity of the disease in patients with obstructive sleep apnea-hypopnea syndrome (OSAHS). Objective: To clarify the effects of nasal continuous positive airway pressure (nCPAP) treatment on plasma orexin-A levels in patients with this syndrome. Method: Sleep tests and blood sample collections were conducted at the sleep-related respiratory disorders clinic and the sleep laboratory of the Iwate Medical University Hospital. We studied 27 patients with OSAHS (apnea-hypopnea index [AHI], ≥ 20 by polysomnography) who were treated with nCPAP for 3 to 6 months. These, patients were divided into the following two groups according to the arousal index (AI): group A (n = 11), ≥ 60; group B (n = 16), < 60. Plasma samples were obtained before and after the nCPAP treatment for 3 to 6 months. Plasma immunoreactive (IR)-orexin-A concentrations were measured by radioimmunoassay after the extraction using cartridges. Results: Plasma IR-orexin-A concentrations were inversely correlated with the AI (r = -0.807; p < 0.0001) and AHI (r = -0.661; p < 0.0001) in 27 patients before the nCPAP treatment. Mean (± SEM) plasma IR-orexin-A concentrations were significantly lower in group A (1.0 ± 0.3 pmol/L) than in group B (4.6 ± 0.4 pmol/L). Mean plasma IR-orexin-A concentrations were significantly increased after the nCPAP treatment in group A (to 3.4 ± 1.2 pmol/L; p = 0.0069), whereas they were not significantly changed in group B. The increases in plasma IR-orexin-A concentrations after the nCPAP treatment were in parallel with the improvements in AI and Epworth sleepiness scale (a marker of severity of daytime excessive sleepiness) score in group A. Conclusions: The low plasma orexin-A levels were increased by the nCPAP treatment in patients with severe OSAHS, suggesting that orexin-A is a plasma marker that reflects the severity of OSAHS and the response to treatment.

Original languageEnglish
Pages (from-to)731-737
Number of pages7
JournalChest
Volume127
Issue number3
DOIs
Publication statusPublished - 2005 Mar

Keywords

  • Adherence
  • Arousal index
  • Continuous positive airway pressure
  • Neuropeptides
  • Orexin
  • Sleep apnea hypopnea syndrome

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Low plasma orexin-A levels were improved by continuous positive airway pressure treatment in patients with severe obstructive sleep apnea-hypopnea syndrome'. Together they form a unique fingerprint.

Cite this